Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

Item

http://www.wikidata.org/entity/Q34486831

Q34486831

about

European guidance for the diagnosis and management of osteoporosis in postmenopausal women Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis Skeletal complications of bisphosphonate use: what the radiologist should know Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project Bone anabolics in osteoporosis: Actuality and perspectives Novel advances in the treatment of osteoporosis.Pharmacological management of osteogenesis.Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Long term bisphosphonate therapy & atypical femoral fractures: a word of caution.Pathological pelvic fracture following long-term bisphosphonate use in a 63-year-old woman.Questioning the association between bisphosphonates and atypical femoral fractures Role of zoledronic acid in the prevention and treatment of osteoporosis.Bisphosphonates and atypical fractures of femur.Clinical utility of denosumab for treatment of bone loss in men and women Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture Long-term safety concerns of antiresorptive therapy.Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications The epidemiology of distal radius fractures.Management of atypical femoral fracture: a scoping review and comprehensive algorithm.Osteoporosis in men: insights for the clinician Atypical femur fractures: a review of the evidence and its implication to clinical practice Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures.Recommendations for preventing fracture in long-term care.The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.Sr-substituted bone cements direct mesenchymal stem cells, osteoblasts and osteoclasts fate.Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta--a case report.Healing of subtrochanteric atypical fractures after strontium ranelate treatment.Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality.Nmp4/CIZ closes the parathyroid hormone anabolic window.A review of periprosthetic femoral fractures associated with total hip arthroplasty.The effect of alendronate treatment on cortical thickness of the proximal femur in postmenopausal women.A case report of long-term bisphosphonate therapy and atypical stress fracture of bilateral femur.Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw.Prognosis factors in the treatment of bisphosphonate-related osteonecrosis of the jaw - Prognostic factors in the treatment of BRONJ.A Case Report of Bisphosphonate-induced Bilateral Osteoporotic Subtrochanteric Fracture Femurii: Review of Literature.Zoledronic acid for prevention and treatment of osteoporosis.Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.Current options for the management of postmenopausal osteoporosis.

P2860

Q24612411-74771469-E340-42DC-A88F-135A26A8B00C Q26864549-EED35E62-7511-49F6-B758-6A130A76B2E2 Q27010157-D0C2E98F-6A50-4789-88E4-D51B67D3AB54 Q27026618-98EA59B8-93A3-4A0E-B0F4-01DBE9B89429 Q27691122-2F246F95-6F60-4390-8E98-F20950C3C7AD Q30248319-6D13587D-B077-4B18-A310-C3754BB6D1F7 Q33729548-2917B943-7055-46D4-9370-D1E3ED9842BE Q34189582-58920E1A-D0FE-481B-9D7B-902527A30A61 Q34272165-78A1EE90-D8B2-47B7-A325-2FEF56D4D8E1 Q34329025-0CA86D7B-9A78-4D00-965D-48BDC0D04877 Q34899110-2C9B7099-5B72-4538-AA9F-D40F74D2D480 Q34984177-65CDBE76-D269-4B79-8473-76157AE3030F Q34986933-9D2FB63D-5295-4178-A6A9-744CD73C04DE Q35092799-77A741A4-03AE-4CA3-84FE-C0DE8B484DCD Q35093147-67B3ED3D-D0D0-425E-94CE-60C0298CA386 Q35570961-F0B227C5-EDA4-40DB-985B-72929A9CC19C Q35780856-2AFF9FC7-98D9-4C98-B2BA-2A5220C7E74A Q35936280-96A10E6F-4D73-4479-BF8C-48559643D5EB Q36027214-9A8DD6D3-E99D-4227-8240-D76BDB266829 Q36056965-4316AFC5-BFB9-4B3D-B0F2-E7184C4F6B13 Q36059445-8B1607B5-11BD-4C98-B8E8-229310BE537C Q36069758-BDF34FE7-A138-4235-9027-D7644F9BAEE0 Q36176941-374ED463-27E9-4A6C-90E6-929AF874BE80 Q36190027-017F8FAC-5483-4F37-B4EA-A9CB0D2CE2A6 Q36258041-D40EE81D-40E3-4C4D-B200-791D7A9286E0 Q36280067-142C8E6C-C792-444F-9D16-546F37009F51 Q36368632-7735B03F-F2DF-4FAF-B481-99E2D96A36BA Q36505624-3C707456-DC98-4AFC-853B-F99260763D88 Q36589370-62021C20-1E25-4806-8572-0DE732A1B241 Q36633388-5CFE4CBC-89BE-437D-B4E9-4F2BFF65B428 Q36650555-0B024823-36A9-4312-9A42-DEEA36A6DF30 Q36687130-DE1B74E0-7259-41FD-BB24-5DB1A05DB155 Q36983288-89CFCD48-6D38-4C04-AFAD-4A65272B1546 Q37018849-96430638-2989-41D6-B72D-5862562A3417 Q37363602-CA38B032-B396-465C-AC07-5230DD437763 Q37605213-8A75B251-6E35-44A0-8387-A7CE922FC2C7 Q37620378-C84978B9-A361-4C08-81C5-F6D2EDEAAA56 Q37850819-1EA9F52B-F8A7-4703-92E0-363135067826 Q37862933-209ACA0E-EC95-4A03-9C85-30F251A2BB41 Q37931985-6A97DF8F-41EF-4990-934B-335AF2361BA2

P2860

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

Item

http://www.wikidata.org/entity/Q34486831

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Subtrochanteric fractures afte ...... oundation Working Group Report

@ast

Subtrochanteric fractures afte ...... oundation Working Group Report

@en

Subtrochanteric fractures afte ...... oundation Working Group Report

@nl

type

Item

label

Subtrochanteric fractures afte ...... oundation Working Group Report

@ast

Subtrochanteric fractures afte ...... oundation Working Group Report

@en

Subtrochanteric fractures afte ...... oundation Working Group Report

@nl

prefLabel

Subtrochanteric fractures afte ...... oundation Working Group Report

@ast

Subtrochanteric fractures afte ...... oundation Working Group Report

@en

Subtrochanteric fractures afte ...... oundation Working Group Report

@nl

P1476

Subtrochanteric fractures afte ...... oundation Working Group Report

@en

P2093

J A Kanis

http://www.w3.org/2001/XMLSchema#string

J-Y Reginster

http://www.w3.org/2001/XMLSchema#string

K Akesson

http://www.w3.org/2001/XMLSchema#string

M Bouxsein

http://www.w3.org/2001/XMLSchema#string

R Rizzoli

http://www.w3.org/2001/XMLSchema#string

S Papapoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate.

Healing of non-displaced fractures produced by fatigue loading of the mouse ulna.

Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Severely suppressed bone turnover: a potential complication of alendronate therapy.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

P2888

s00198-010-1453-5

P304

373-390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S00198-010-1453-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Cyrus Cooper

Nicola Napoli

P577

2010-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47813197

http://www.w3.org/2001/XMLSchema#string

P6179

1012014089

http://www.w3.org/2001/XMLSchema#string

P698

21085935

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

pathologic fracture

organophosphorus compound

osteoarthritis

P932

3020314

http://www.w3.org/2001/XMLSchema#string

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

about

P2860

P2860

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P921

P932